Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.18 on revenue of $9.19M. Analysts polled by Investing.com anticipated EPS of $-0.2 on revenue of $8.53M.
Nabriva Therapeutics shares are down 2% from the beginning of the year, still down 85.93% from its 52 week high of $1.40 set on November 5, 2021. They are outperforming the S&P 500 which is down 12.82% from the start of the year.
Nabriva Therapeutics shares gained 1.52% in after-hours trade following the report.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar